ATA131094A - Prevention und behandlung ischemischer vorfälle und hieraus resultierender perfusionsverletzungen - Google Patents

Prevention und behandlung ischemischer vorfälle und hieraus resultierender perfusionsverletzungen

Info

Publication number
ATA131094A
ATA131094A AT0131094A AT131094A ATA131094A AT A131094 A ATA131094 A AT A131094A AT 0131094 A AT0131094 A AT 0131094A AT 131094 A AT131094 A AT 131094A AT A131094 A ATA131094 A AT A131094A
Authority
AT
Austria
Prior art keywords
plasminogen
lys
treatment
ischemical
incidents
Prior art date
Application number
AT0131094A
Other languages
English (en)
Other versions
AT407706B (de
Inventor
Johann Dr Eibl
Ludwig Pichler
Hans-Peter Schwarz
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of ATA131094A publication Critical patent/ATA131094A/de
Application granted granted Critical
Publication of AT407706B publication Critical patent/AT407706B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Electrotherapy Devices (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT0131094A 1993-07-02 1994-07-01 Prevention und behandlung ischemischer vorfälle und hieraus resultierender perfusionsverletzungen AT407706B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8803393A 1993-07-02 1993-07-02

Publications (2)

Publication Number Publication Date
ATA131094A true ATA131094A (de) 2000-10-15
AT407706B AT407706B (de) 2001-05-25

Family

ID=22208925

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94110267T ATE167400T1 (de) 1993-07-02 1994-07-01 Lys-plasminogen in der verhütung und behandlung von ischämie und reperfusionschäden
AT0131094A AT407706B (de) 1993-07-02 1994-07-01 Prevention und behandlung ischemischer vorfälle und hieraus resultierender perfusionsverletzungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT94110267T ATE167400T1 (de) 1993-07-02 1994-07-01 Lys-plasminogen in der verhütung und behandlung von ischämie und reperfusionschäden

Country Status (19)

Country Link
US (2) US5520912A (de)
EP (1) EP0631786B1 (de)
JP (1) JP2784146B2 (de)
AT (2) ATE167400T1 (de)
AU (1) AU680492B2 (de)
CA (1) CA2127199C (de)
CZ (1) CZ283352B6 (de)
DE (1) DE69411084T2 (de)
DK (1) DK0631786T3 (de)
ES (1) ES2119934T3 (de)
GR (1) GR3027778T3 (de)
HR (1) HRP940381B1 (de)
HU (1) HU217961B (de)
NO (1) NO942367L (de)
PL (1) PL304061A1 (de)
RU (1) RU2153353C2 (de)
SI (1) SI0631786T1 (de)
SK (1) SK281472B6 (de)
ZA (1) ZA944522B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
WO2000018436A1 (en) * 1998-09-29 2000-04-06 Leuven Research & Development Vzw Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
EP1062953A1 (de) * 1999-06-22 2000-12-27 Leuven Research & Development vzw Verwendung von Verbindungen, die Alpha2-Antiplasmin in vivo reduzieren, zur Herstellung einer Zusammensetzung zur Behandlung ischämischer Schlaganfälle
US7184963B1 (en) 1999-01-19 2007-02-27 Bristol-Myers Squibb Company Method for determining care and prevention pathways for clinical management of wounds
WO2000041714A1 (en) * 1999-01-19 2000-07-20 Bristol-Myers Squibb Company Method for determining care and prevention pathways for clinical management of wounds
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
US7479270B2 (en) * 2002-07-23 2009-01-20 Vegenics Limited Methods and compositions for activating VEGF-D and VEGF-C
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
RU2341256C1 (ru) * 2007-03-26 2008-12-20 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ профилактики реперфузионных осложнений у пациентов, оперированных по поводу хронической ишемии нижних конечностей
RU2411911C1 (ru) * 2009-07-02 2011-02-20 Клиника государственного образовательного учреждения высшего профессионального образования "Челябинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию"(Клиника ГОУ ВПО ЧелГМА Роздрава) Способ прогнозирования характера течения реперфузионного синдрома после поэтапного хирургического лечения сонных артерий у пациентов с симптомными бикаротидными стенозами
EP2451835A1 (de) 2009-07-10 2012-05-16 ThromboGenics N.V. Varianten von plasminogen und plasmin
ES2534911T3 (es) 2009-08-28 2015-04-30 Thrombogenics N.V. Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía
RU2604807C2 (ru) 2011-01-05 2016-12-10 ТромбоДженикс НВ Варианты плазминогена и плазмина
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
TW201822805A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療脂肪異常沉積導致的組織損傷的方法
TW201829448A (zh) 2016-12-15 2018-08-16 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
EP3556385A4 (de) * 2016-12-15 2020-12-30 Talengen International Limited Verfahren zur verringerung von herzerkrankungen
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
RU2729788C2 (ru) * 2018-09-04 2020-08-12 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Пущинский научный центр биологических исследований Российской академии наук" Средство, его применение и способ повышения устойчивости организма млекопитающих к ишемически-реперфузионному поражению тонкого кишечника
EP3914288A1 (de) 2019-01-24 2021-12-01 PreviPharma Consulting GmbH Plasminogen zur behandlung und vorbeugung von mikrothrombose
IL287036B2 (en) * 2019-04-12 2025-07-01 Uglk Science Ab Method and apparatus for reconditioning kidneys
MX2021012242A (es) * 2019-04-12 2021-12-10 Uglx Res Ab Metodo y aparato para reacondicionar organos.
CN114642722A (zh) * 2020-12-18 2022-06-21 四川大学华西医院 纤溶酶原用于制备促进血管新生的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (de) * 1979-11-05 1983-10-05 Beecham Group Plc Enzym-Derivate und ihre Herstellung
JPH0680015B2 (ja) * 1986-05-12 1994-10-12 ザ ウエルカム ファウンデーション リミテッド 医薬組成物
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AT390801B (de) * 1988-07-28 1990-07-10 Immuno Ag Verfahren zur herstellung von lys-plasminogen
US5358936A (en) * 1990-08-03 1994-10-25 Paul Gordon Anionic furanose derivatives, methods of making and using the same
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen

Also Published As

Publication number Publication date
ATE167400T1 (de) 1998-07-15
EP0631786A1 (de) 1995-01-04
SK281472B6 (sk) 2001-04-09
RU94022754A (ru) 1996-08-10
JP2784146B2 (ja) 1998-08-06
US5520912A (en) 1996-05-28
AT407706B (de) 2001-05-25
HRP940381A2 (en) 1997-04-30
JPH07145076A (ja) 1995-06-06
HU9401983D0 (en) 1994-09-28
RU2153353C2 (ru) 2000-07-27
CA2127199C (en) 2000-11-28
DK0631786T3 (da) 1999-04-06
GR3027778T3 (en) 1998-11-30
CA2127199A1 (en) 1995-01-03
CZ283352B6 (cs) 1998-03-18
HU217961B (hu) 2000-05-28
PL304061A1 (en) 1995-01-09
CZ161394A3 (en) 1995-01-18
AU6485494A (en) 1995-01-12
NO942367L (no) 1995-01-03
HRP940381B1 (en) 1999-06-30
US5597800A (en) 1997-01-28
ES2119934T3 (es) 1998-10-16
DE69411084D1 (de) 1998-07-23
HUT67225A (en) 1995-03-28
EP0631786B1 (de) 1998-06-17
SK79894A3 (en) 1995-05-10
ZA944522B (en) 1995-02-23
SI0631786T1 (en) 1998-10-31
DE69411084T2 (de) 1998-12-03
NO942367D0 (de) 1994-06-21
AU680492B2 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
ES2119934T3 (es) Lys-plasminogeno en la prevencion y tratamiento de la isquemia y las lesiones de reperfusion.
NO885109D0 (no) FremgangsmŸte og middel for Ÿ forhindre blodpropp.
ATE243029T1 (de) Transdermales system zur verabreichung durch entepithelisierte haut
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
ATE233099T1 (de) Eine formulierung des gerinnungsfaktors viii
Klement et al. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model
Paletta et al. Prolonged tourniquet ischemia of extremities: An experimental study on dogs
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
DE69832176D1 (de) Arzneimittel gegen diabetes-komplikationen
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
ES2211996T3 (es) Agentes de union a receptores de acido hialuronico y su uso para el tratamiento de tumores o de reestenosis.
Sibley et al. The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid
ATE78292T1 (de) Plasminogen-aktivator und thrombolytische zusammensetzung.
DK0381640T3 (da) Thrombolytiske præparater
DK164640C (da) Farmaceutisk praeparat med thrombolytisk aktivitet og fremgangsmaade til fremstilling deraf
Zenz et al. Thrombolytic therapy in pediatric patients
DE69724818D1 (de) Medizinische Verwendung des scuPA/suPAR Komplexes
Kubo et al. On the Treatment of the Fracture Associated with Serious Head Injury
GABOVICH et al. STUDY OF OZONE TREATMENT OF THE DNIEPER WATER(IN RUSSIAN)
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
Prevot et al. Reducing “DVT hard core” through veinous stimulation report on 300 hip arthtroplasties
Senior Thrombolysis without bleeding
Le Querrec et al. Mode of action of aprotinin in the reduction of bleeding during orthotopic liver transplantation (OLT)
Brackmann Treatment of Factor VIII Inhibitor Patients

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee